发明名称 Modulators of HEC1 activity and methods therefor
摘要 Compounds, compositions, and methods for modulation of Hec1/Nek2 interaction are provided. Especially preferred compounds disrupt Nek2/Hec1 binding and are therefore useful as chemotherapeutic agent for neoplastic diseases.
申请公布号 US9409902(B2) 申请公布日期 2016.08.09
申请号 US201414527087 申请日期 2014.10.29
申请人 Taivex Therapeutics Corporation 发明人 Lau Johnson;Huang Jiann-Jyh
分类号 A61K31/4436;C07D417/14;A61K31/427;A61K31/4439;A61K31/496;A61K31/501;A61K31/506;A61K31/5377;C07D417/12;A61K31/426;A61K31/444;A61K31/4545;C07D277/44 主分类号 A61K31/4436
代理机构 Lewis Roca Rothgerber Christie LLP 代理人 Lewis Roca Rothgerber Christie LLP
主权项 1. A method of treating a neoplastic disease, comprising: administering to a mammal in need thereof a pharmaceutical composition comprising a compound having a structure according to Formula I R1 is alkyl, ORa, SRa, or —S(O)2Ra; Ra is alkyl, or aryl substituted with alkoxy; R2 and R3 are independently alkyl; R4 is hydrogen; R5 is pyridyl optionally substituted with alkyl, fluoroalkyl, halogen, or alkoxy; wherein the compound is present in the composition an amount effective to disrupt Hec1/Nek2 binding in the mammal when the composition is administered to the mannal; and wherein the neoplastic disease is selected from the group consisting of breast cancer, prostate cancer, cervical cancer and leukemia.
地址 Taipei TW